Amedisys (AMED) Tops Q3 EPS by 2c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amedisys (AMED) PT Raised to $64 at Jefferies
November 8, 2017 8:35 AM ESTJefferies raised its price target on Amedisys (NASDAQ: AMED) to $64.00 (from $60.00) while maintaining a Buy rating following Q3.
Analyst Brian Tanquilut said the 5% SS increase in Medicare episodes highlights early traction the company is seeing with its revamped sales force and growth initiatives.
... More